A growing number of prominent figures within Elon Musk's personal and professional orbit have been directing significant financial resources toward psychedelic therapeutics companies, part of a broader push to move drugs like MDMA and psilocybin from the fringes of medicine into mainstream mental he...
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.